Xencor, Inc. (XNCR)
| Market Cap | 2.22B +133.9% |
| Revenue (ttm) | 104.97M -28.6% |
| Net Income | -163.33M |
| EPS | -2.18 |
| Shares Out | 74.35M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 999,397 |
| Open | 29.74 |
| Previous Close | 29.18 |
| Day's Range | 27.76 - 30.09 |
| 52-Week Range | 10.38 - 33.60 |
| Beta | 0.90 |
| Analysts | Buy |
| Price Target | 40.25 (+34.98%) |
| Est. Earnings | Nov 9, 2026 |
About XNCR
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It also develops XmAb819, a bispecific antibody to treat renal cell carcinoma; XmAb541, which is in Phase... [Read more]
Financial Performance
In 2025, Xencor's revenue was $125.58 million, an increase of 13.65% compared to the previous year's $110.49 million. Losses were -$91.92 million, -60.48% less than in 2024.
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for XNCR stock is "Buy." The 12-month stock price target is $40.25, which is an increase of 34.98% from the latest price.
News
Xencor price target raised to $43 from $20 at RBC Capital
RBC Capital raised the firm’s price target on Xencor (XNCR) to $43 from $20 and keeps an Outperform rating on the shares. The company presented updated data from their XmAb819…
Xencor price target raised to $40 from $29 at Truist
Truist raised the firm’s price target on Xencor (XNCR) to $40 from $29 and keeps a Buy rating on the shares. The firm is positive on the company’s compelling ESMO…
Xencor price target raised to $40 from $29 at Truist
Truist raised the firm’s price target on Xencor (XNCR) to $40 from $29 and keeps a Buy rating on the shares. The firm is positive on the company’s compelling ESMO…
Xencor price target raised to $45 from $30 at Wedbush
Wedbush analyst David Nierengarten raised the firm’s price target on Xencor (XNCR) to $45 from $30 and keeps an Outperform rating on the shares. Following the positive ESMO update, Xencor…
Xencor price target raised to $45 from $35 at Barclays
Barclays raised the firm’s price target on Xencor (XNCR) to $45 from $35 and keeps an Overweight rating on the shares. The firm says the “strong” data over the weekend…
Xencor Transcript: Study update
XmAb819 showed dose-related antitumor activity in heavily pretreated clear cell RCC, with ORRs of 30%, 44% and 45.5% at 100, 200 and 400 µg/kg. The 400 µg/kg dose was selected for planned 2027 pivotal development; safety was consistent across dose cohorts.
Xencor Press release: Study update
Xencor issued a press release on October 26, 2026, disclosing material business information to investors.
Xencor Slides: Study update
Xencor has posted slides in relation to its latest quarterly earnings report, which was published on October 26, 2026.
Xencor announces updated results from Phase 1 study of XmAb819
Xencor (XNCR) announced updated results from the Phase 1 study of XmAb819, an ENPP3 x CD3 T-cell engaging bispecific antibody, in patients with advanced clear cell renal cell carcinoma, ccRCC.
Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Patients With Advanced Clear Cell Renal Cell Carcinoma and ENPP3+ Tumors
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today an...
Xencor to discuss results from Phase 1 study of XmAb819
Xencor (XNCR) to discuss results from the Phase 1 Study of XmAb819, an ENPP3 x CD3 T-cell engaging bispecific antibody, in development for patients with advanced clear cell renal cell…
Xencor to Host Webcast to Discuss Results From the Phase 1 Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, will hos...
Xencor price target raised to $26 from $20 at BofA
BofA raised the firm’s price target on Xencor (XNCR) to $26 from $20 and keeps a Neutral rating on the shares. Despite falling off all-time highs over the past month,…
Xencor price target raised to $35 from $27 at Barclays
Barclays raised the firm’s price target on Xencor (XNCR) to $35 from $27 and keeps an Overweight rating on the shares. The firm updated the company’s model post the Q2…
Xencor Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
The session highlighted the transition to late-stage development with pivotal studies for proprietary T-cell engagers, notably ENPP3 in RCC, and a robust pipeline in oncology and immunology. Key data readouts are expected at ESMO and in phase II-B UC studies, with combination and bispecific strategies advancing.
Xencor Slides: Corporate presentation
Xencor has posted slides in relation to its latest quarterly earnings report, which was published on September 9, 2026.
Xencor price target raised to $21 from $14 at JPMorgan
JPMorgan analyst Brian Cheng raised the firm’s price target on Xencor (XNCR) to $21 from $14 and keeps a Neutral rating on the shares. The firm updated the company’s model.
Xencor to Present at the 2026 Cantor Global Healthcare Conference
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today an...
Xencor price target raised to $46 from $40 at Raymond James
Raymond James raised the firm’s price target on Xencor (XNCR) to $46 from $40 and keeps a Strong Buy rating on the shares ahead of the company’s planned presentation of…
Xencor price target raised to $30 from $26 at Wedbush
Wedbush analyst David Nierengarten raised the firm’s price target on Xencor (XNCR) to $30 from $26 and keeps an Outperform rating on the shares following quarterly results and program updates.
Xencor price target raised to $44 from $43 at Cantor Fitzgerald
Cantor Fitzgerald analyst Steve Seedhouse raised the firm’s price target on Xencor (XNCR) to $44 from $43 and keeps an Overweight rating on the shares.
Xencor price target raised to $20 from $19 at RBC Capital
RBC Capital raised the firm’s price target on Xencor (XNCR) to $20 from $19 and keeps an Outperform rating on the shares.
Xencor reports Q2 EPS (29c), consensus (84c)
Reports Q2 revenue $51.122M vs $43.608M last year. “We are excited to present XmAb819 results at ESMO this fall and for other fast-approaching key milestones across our wholly owned clinical…
Xencor Reports Second Quarter 2026 Financial Results
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today re...
Xencor Earnings release: Q2 2026
Xencor released its Q2 2026 earnings on August 5, 2026, summarizing the period's financial results.